Washed Microbiota Transplantation for Malnutrition

July 6, 2025 updated by: Faming Zhang, The Second Hospital of Nanjing Medical University
Malnutrition is a pathological condition in which dietary intake fails to meet the body's energetic or nutritional needs. It may be caused by macronutrient or micronutrient deficiencies, high energy expenditure, impaired nutrient absorption or assimilation. Malnutrition can affect all stages of life. In adults, malnutrition is strongly associated with poor clinical outcomes such as increased morbidity, increased mortality and prolonged hospitalization. In children, malnutrition can lead to growth retardation, cognitive impairment and immune dysfunction.

Study Overview

Status

Recruiting

Conditions

Detailed Description

The gut microbiota of malnourished patients is different from that of healthy people. The diversity of the gut microbiota of patients with severe malnutrition reduced and the abundance of Proteobacteria significantly increased, as well as pathogenic genera such as Klebsiella, Escherichia coli, Shigella, and Streptococcus. This suggests that gut microbiota plays an important role in the occurrence and development of malnutrition. Dietary intervention targeting gut microbiota can quickly improve children's malnutrition, promote weight gain and increase protein levels that promote bone growth and nerve development. Exclusive enteral nutrition combined with immediate washed microbiota transplantation(WMT) can rapidly improve the nutritional status of patients with Crohn's disease compared with those with delayed WMT. Gut microbiota has been confirmed to be closely related to malnutrition. Improving the disordered gut microbiota in malnourished patients may become a potential treatment.

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Jiangsu
      • Nanjing, Jiangsu, China
        • Recruiting
        • Department of Microbiota Medicine & Medical Centre for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with malnutrition receiving WMT will be enrolled.

Description

Inclusion Criteria:

  1. Age ≥18 years old;
  2. Meet any of the following two conditions: ①weight loss (>5% weight loss in the past 6 months or >10% weight loss in more than 6 months); ②low BMI (<70 years old and BMI<18.5kg/m2 or ≥70 years old and BMI<22kg/m2);
  3. Underwent washed microbiota transplantation.

Exclusion Criteria:

  1. Expected survival time <3 months;
  2. Women who are pregnant or breastfeeding;
  3. Other patients deemed not suitable for enrollment by the investigator.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
The malnourished undergoing washed microbiota transplantation
patients undergoing washed microbiota transplantation who were diagnosed as malnutrition according to weight loss or low BMI
The prepared microbiota suspension was infused into the patients' gut.
Other Names:
  • fecal microbiota transplantation
The malnourished not undergoing washed microbiota transplantation
The malnourished patients did not undergo washed microbiota transplantation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change of the third lumbar vertebrae skeletal muscle mass and height
Time Frame: baseline, 12 weeks post transplantation
The third lumbar vertebrae skeletal muscle mass represents the sum of the cross-sectional areas of the skeletal muscles at the L3 level, including the psoas major, the erector spinae, the quadratus lumborum, the musculus transversus abdominis, the obliquus externus abdominis and the obliquus internus abdominis. Skeletal muscle mass and height will be combined to report the third lumbar vertebrae skeletal muscle mass index(L3 SMI) in cm^2/m^2.
baseline, 12 weeks post transplantation
change of weight and height
Time Frame: baseline, 4 weeks, 8 weeks, 12 weeks post transplantation
Weight and height will be combined to report BMI in kg/m^2.
baseline, 4 weeks, 8 weeks, 12 weeks post transplantation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change of the 5-level EuroQoL Group's 5-dimension (EQ-5D-5L)
Time Frame: baseline, 4 weeks, 8 weeks, 12 weeks post transplantation
EQ-5D-5L is a 5-dimension questionnaire measuring health state and each dimension represents the level from 1 to 5, with higher level indicating worse health state.
baseline, 4 weeks, 8 weeks, 12 weeks post transplantation
change of the Pittsburgh Sleep Quality Index (PSQI)
Time Frame: baseline, 4 weeks, 8 weeks, 12 weeks post transplantation
PSQI is a self-rated questionnaire which assesses sleep quality over a 1-month time interval. Nineteen items generate seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for seven components yields one global score, with higher score indicating worse sleep quality.
baseline, 4 weeks, 8 weeks, 12 weeks post transplantation
change of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)
Time Frame: baseline, 4 weeks, 8 weeks, 12 weeks post transplantation
FACIT-Fatigue is a 13-item test measuring fatigue and each item receives a value from 0 to 4, with higher value indicating worse fatigue state.
baseline, 4 weeks, 8 weeks, 12 weeks post transplantation
change of the Gastrointestinal Symptom Rating Scale(GSRS)
Time Frame: baseline, 4 weeks, 8 weeks, 12 weeks post transplantation
GSRS is a 13-item test to make a comprehensive assessment of common gastrointestinal symptom and each item receives a value from 0 to 3, with higher value indicating worse gastrointestinal condition.
baseline, 4 weeks, 8 weeks, 12 weeks post transplantation
change of insulin-like growth factor I(IGF-I)
Time Frame: baseline, 12 weeks post transplantation
Blood is tested for Insulin-like growth factor I.
baseline, 12 weeks post transplantation
the difference of the gut microbiota composition before and after washed microbiota transplantation
Time Frame: baseline, 12 weeks post transplantation
The composition of the gut microbiota is evaluated by sequencing faecal metagenome. We evaluate the differences in the structure of the flora and its metabolism.
baseline, 12 weeks post transplantation
the incidence of treatment-related adverse events (AE) assessed by CTCAE, Version 5.0
Time Frame: 12 weeks post transplantation
The severity of AE was graded as mild (grade 1), moderate (grade 2), severe/disabling (grade 3), life threatening (grade 4), and death (grade 5). All AE were divided in definitely, probably and possibly related to treatment. The treatment-related AE we focused on included microbiota-related AEs (e.g., infection, diarrhea, abdominal pain, etc.) and route of delivery related AEs (e.g., nausea, vomiting, etc.).
12 weeks post transplantation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Faming Zhang, PhD, The Second Hospital of Nanjing Medical University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 17, 2023

Primary Completion (Estimated)

December 1, 2030

Study Completion (Estimated)

April 1, 2031

Study Registration Dates

First Submitted

May 19, 2024

First Submitted That Met QC Criteria

June 5, 2024

First Posted (Actual)

June 7, 2024

Study Record Updates

Last Update Posted (Actual)

July 10, 2025

Last Update Submitted That Met QC Criteria

July 6, 2025

Last Verified

July 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • WMT-MN-2024

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Malnutrition

Clinical Trials on washed microbiota transplantation

Subscribe